Literature DB >> 10369916

The human CD38 gene: polymorphism, CpG island, and linkage to the CD157 (BST-1) gene.

E Ferrero1, F Saccucci, F Malavasi.   

Abstract

CD38 is a leukocyte activation antigen and ectoenzyme [NAD(P)+ glycohydrolase; EC 3.2.2.6] involved in numerous immune functions. The human CD38 gene is complex [eight exons, >80 kilobases (kb) long] located on Chromosome 4p15, and part of the eukaryotic NAD+ glycohydrolase/ADP-ribosyl cyclase gene family. Because of the increasing relevance of the CD38 molecule in the host immune response to infectious, tumoral, and metabolic diseases, we investigated the genetic variability and linkage of the human CD38 locus. We report that (1) the restriction endonuclease Pvu II identifies a bi-allelic polymorphism here defined as formed by the alleles CD38*A (12 kb) and CD38*B (9/2.5 kb); (2) their frequency in the healthy Italian Caucasian population is 14% and 86%, respectively; (3) the polymorphic Pvu II site is located at the 5' end of the first intron of the CD38 gene; (4) in conjunction with the polymorphic site, we identified a 900 base pair CpG island associated with the CD38 gene, with two potential Sp1 binding sites; (5) the CpG island may play a role in the regulation of CD38 expression and is hypomethylated in various cell lines; (6) by pulsed-field gel electrophoresis we show that CD38 and its paralogue, the bone-marrow stromal cell antigen BST-1 (CD157), map to the same 800 kb Avi II fragment, indicating that the two human ecto-NADase genes are closely linked.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10369916     DOI: 10.1007/s002510050654

Source DB:  PubMed          Journal:  Immunogenetics        ISSN: 0093-7711            Impact factor:   2.846


  26 in total

Review 1.  CD38 and CD157 as receptors of the immune system: a bridge between innate and adaptive immunity.

Authors:  Fabio Malavasi; Silvia Deaglio; Enza Ferrero; Ada Funaro; Jaime Sancho; Clara M Ausiello; Erika Ortolan; Tiziana Vaisitti; Mercedes Zubiaur; Giorgio Fedele; Semra Aydin; Elena V Tibaldi; Ilaria Durelli; Riccardo Lusso; Franco Cozno; Alberto L Horenstein
Journal:  Mol Med       Date:  2006 Nov-Dec       Impact factor: 6.354

2.  CD38 expression, function, and gene resequencing in a human lymphoblastoid cell line-based model system.

Authors:  William R Hartman; Linda L Pelleymounter; Irene Moon; Krishna Kalari; Mohan Liu; Tse-Yu Wu; Carlos Escande; Veronica Nin; Eduardo N Chini; Richard M Weinshilboum
Journal:  Leuk Lymphoma       Date:  2010-07

3.  CD38 is associated with premenopausal and postmenopausal bone mineral density and postmenopausal bone loss.

Authors:  Frances J Drummond; John J Mackrill; Kathleen O'sullivan; Mary Daly; Fergus Shanahan; Michael G Molloy
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 4.  CD38 and chronic lymphocytic leukemia: a decade later.

Authors:  Fabio Malavasi; Silvia Deaglio; Rajendra Damle; Giovanna Cutrona; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-07-15       Impact factor: 22.113

5.  Evidence for a role of the oxytocin system, indexed by genetic variation in CD38, in the social bonding effects of expressed gratitude.

Authors:  Sara B Algoe; Baldwin M Way
Journal:  Soc Cogn Affect Neurosci       Date:  2014-01-05       Impact factor: 3.436

Review 6.  CD38 autoimmunity: recent advances and relevance to human diabetes.

Authors:  A Antonelli; E Ferrannini
Journal:  J Endocrinol Invest       Date:  2004 Jul-Aug       Impact factor: 4.256

7.  CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools.

Authors:  Jeffrey P Chmielewski; Sarah C Bowlby; Frances B Wheeler; Lihong Shi; Guangchao Sui; Amanda L Davis; Timothy D Howard; Ralph B D'Agostino; Lance D Miller; S Joseph Sirintrapun; Scott D Cramer; Steven J Kridel
Journal:  Mol Cancer Res       Date:  2018-08-03       Impact factor: 5.852

Review 8.  Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule.

Authors:  Antonella Chillemi; Gianluca Zaccarello; Valeria Quarona; Manuela Ferracin; Chiara Ghimenti; Massimo Massaia; Alberto L Horenstein; Fabio Malavasi
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

9.  Nicotinamide cooperates with retinoic acid and 1,25-dihydroxyvitamin D(3) to regulate cell differentiation and cell cycle arrest of human myeloblastic leukemia cells.

Authors:  Miaoqing Shen; Andrew Yen
Journal:  Oncology       Date:  2009-01-06       Impact factor: 2.935

10.  Structural basis for enzymatic evolution from a dedicated ADP-ribosyl cyclase to a multifunctional NAD hydrolase.

Authors:  Qun Liu; Richard Graeff; Irina A Kriksunov; Hong Jiang; Bo Zhang; Norman Oppenheimer; Hening Lin; Barry V L Potter; Hon Cheung Lee; Quan Hao
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.